TITLE

Test may separate benign from aggressive prostate cancer

AUTHOR(S)
BREINDL, ANETTE
PUB. DATE
February 2009
SOURCE
Medical Device Daily;2/13/2009, Vol. 13 Issue 29, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the potential role of sarcosine, a type of amino acid, in separating aggressive from indolent cancers. It was identified by a team from the University of Michigan, Ann Arbor, Pennsylvania State University, State College and Metabolon of Durham, North Carolina. They note that medically, sarcosine may be useful in two ways. First, it can serve as a biomarker for prostate cancer aggressiveness and second, it may actually be involved in the biology of cancer aggressiveness and invasiveness.
ACCESSION #
36500684

 

Related Articles

  • Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Crea, Francesco; Hurt, Elaine M.; Mathews, Lesley A.; Cabarcas, Stephanie M.; Lei Sun; Marquez, Victor E.; Danesi, Romano; Farrar, William L. // Molecular Cancer;2011, Vol. 10 Issue 1, p40 

    Background: Polycomb repressive complex 2 (PRC2) mediates gene silencing through histone H3K27 methylation. PRC2 components are over-expressed in metastatic prostate cancer (PC), and are required for cancer stem cell (CSC) self-renewal. 3-Dezaneplanocin-A (DZNeP) is an inhibitor of PRC2 with...

  • Sequential maximum androgen blockade (MAB) in minimally symptomatic prostate cancer progressing after initial MAB: two case reports. Hingorani, Mohan; Dixit, Sanjay; Bashir, Fahim; Butt, Mohammad; Hawkyard, Simon; Khafagy, Richard; Robertson, Andrew // Cancer Biology & Medicine;Dec2014, Vol. 11 Issue 4, p277 

    The management of castrate-resistant prostate cancer progressing after maximum androgen blockade (MAB) has evolved in the last decade with the development of several novel therapeutic options. However, the initial therapeutic strategy in these patients usually involves withdrawal of...

  • AUTHOR'S REPLY. Takehiro Sejima // Central European Journal of Urology;2013, Vol. 66 Issue 2, p135 

    In this article the author comments about views on their article on discovering preoperative non-tumor related biomarkers which can easily be obtained by routine laboratory examination. The author says that delayed diagnostic procedure may be responsible for micro metastases progression of...

  • Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Riddick, A. C. P.; Shukla, C. J.; Pennington, C. J.; Bass, R.; Nuttall, R. K.; Hogan, A.; Sethia, K. K.; Ellis, V.; Collins, A. T.; Maitland, N. J.; Ball, R. Y.; Edwards, D. R. // British Journal of Cancer;6/20/2005, Vol. 92 Issue 12, p2171 

    Extracellular proteases of the matrix metalloproteinase (MMP) and serine protease families participate in many aspects of tumour growth and metastasis. Using quantitative real-time RT–PCR analysis, we have undertaken a comprehensive survey of the expression of these enzymes and of their...

  • MTA family of proteins in prostate cancer: biology, significance, and therapeutic opportunities. Levenson, Anait; Kumar, Avinash; Zhang, Xu // Cancer & Metastasis Reviews;Dec2014, Vol. 33 Issue 4, p929 

    This review summarizes our current understanding of the role of MTA family members, particularly MTA1, with a special emphasis on prostate cancer. The interest for the role of MTA1 in prostate cancer was boosted from our initial findings of MTA1 as a component of 'vicious cycle' and a member of...

  • Prostate cancer epigenetic biomarkers: next-generation technologies. Valdés-Mora, F; Clark, S J // Oncogene;3/26/2015, Vol. 34 Issue 13, p1609 

    Cancer is caused by a combination of genetic alterations and gross changes to the epigenetic landscape that together result in aberrant cancer gene regulation. Therefore, we need to fully sequence both the cancer genome and the matching cancer epigenomes before we can fully integrate the suite...

  • PCa biomarkers under investigation.  // Urology Times;Oct2002, Vol. 30 Issue 10, p32 

    Lists prostate cancer biomarkers being investigated in the U.S., current as of October 2002. Hepsin; Caveolin 1; RNase L; Human glandular kallikrein.

  • Biomarker panel identified prostate cancer with 90% accuracy. Harris, Jason; Southall, Jennifer // Hem/Onc Today;10/25/2010, Vol. 11 Issue 20, p20 

    The article discusses research being done on the use of biomarkers for detecting prostate cancer and prostate disease, which references a study by John Anson and colleagues presented at the American Association for Cancer Research (AACR) International Conference in Denver, Colorado from...

  • Bloodborne biomolecular markers in prostate cancer development and progression. Bok, Robert A.; Small, Eric J. // Nature Reviews Cancer;Dec2002, Vol. 2 Issue 12, p918 

    Prostate cancer is notoriously difficult to treat, which makes its early detection a priority. Biomarkers have been used to diagnose and monitor prostate cancer for more than 50 years, and the discovery of the serum marker prostate-specific antigen (PSA) significantly altered the detection and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics